Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.04M | 13.86M | 13.86M | 2.82M | 2.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.04M | 13.86M | 13.86M | 2.82M | 2.82M |
| Cost of Revenue | 2.39M | 2.39M | 2.39M | 0.00 | 0.00 |
| Gross Profit | 8.65M | 11.47M | 11.47M | 2.82M | 2.82M |
| SG&A Expenses | 22.80M | 18.01M | 19.62M | 19.44M | 19.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.75M | 97.03M | 95.70M | 85.45M | 85.73M |
| Operating Income | -89.71M | -83.18M | -81.85M | -82.63M | -82.91M |
| Income Before Tax | -87.62M | -80.35M | -78.24M | -98.97M | -98.17M |
| Income Tax Expenses | 1.10M | 1.39M | 1.39M | -1.88M | -1.88M |
| Earnings from Continuing Operations | -88.73 | -81.74 | -79.62 | -97.09 | -96.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.73M | -81.74M | -79.62M | -97.09M | -96.29M |
| EBIT | -89.71M | -83.18M | -81.85M | -82.63M | -82.91M |
| EBITDA | -85.53M | -78.76M | -77.33M | -80.47M | -80.54M |
| EPS Basic | -1.40 | -1.30 | -1.28 | -1.58 | -1.57 |
| Normalized Basic EPS | -0.87 | -0.80 | -0.79 | -0.79 | -0.79 |
| EPS Diluted | -1.40 | -1.30 | -1.28 | -1.58 | -1.57 |
| Normalized Diluted EPS | -0.87 | -0.80 | -0.79 | -0.79 | -0.79 |
| Average Basic Shares Outstanding | 253.05M | 250.98M | 248.56M | 246.77M | 244.93M |
| Average Diluted Shares Outstanding | 253.05M | 250.98M | 248.56M | 246.77M | 244.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |